137 related articles for article (PubMed ID: 37163938)
1. Tripterygium glycosides reverse chemotherapy resistance in ovarian cancer by targeting the NRF2/GPX4 signal axis to induce ferroptosis of drug-resistant human epithelial ovarian cancer cells.
Ma B; Zhong Y; Chen R; Zhan X; Huang G; Xiong Y; Tan B
Biochem Biophys Res Commun; 2023 Jul; 665():178-186. PubMed ID: 37163938
[TBL] [Abstract][Full Text] [Related]
2. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
Fu D; Wang C; Yu L; Yu R
Cell Mol Biol Lett; 2021 Jun; 26(1):26. PubMed ID: 34098867
[TBL] [Abstract][Full Text] [Related]
3. Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe
Ni M; Zhou J; Zhu Z; Xu Q; Yin Z; Wang Y; Zheng Z; Zhao H
Phytomedicine; 2023 Apr; 112():154701. PubMed ID: 36773431
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
5. The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin.
Liu Q; Wang K
Cell Biol Int; 2019 Nov; 43(11):1245-1256. PubMed ID: 30811078
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
7. The Nrf2/PGC1
Deng X; Lin N; Fu J; Xu L; Luo H; Jin Y; Liu Y; Sun L; Su J
Oxid Med Cell Longev; 2020; 2020():4830418. PubMed ID: 33294122
[TBL] [Abstract][Full Text] [Related]
8. Yi-qi-hua-yu-jie-du decoction induces ferroptosis in cisplatin-resistant gastric cancer via the AKT/GSK3β/NRF2/GPX4 axis.
Huang W; Wen F; Yang P; Li Y; Li Q; Shu P
Phytomedicine; 2024 Jan; 123():155220. PubMed ID: 38056149
[TBL] [Abstract][Full Text] [Related]
9. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
10. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
[TBL] [Abstract][Full Text] [Related]
11. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin.
Takahashi R; Kamizaki K; Yamanaka K; Terai Y; Minami Y
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37144519
[TBL] [Abstract][Full Text] [Related]
13. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
14. AKT1 participates in ferroptosis vulnerability by driving autophagic degradation of FTH1 in cisplatin-resistant ovarian cancer.
Shi Z; Yuan H; Cao L; Lin Y
Biochem Cell Biol; 2023 Oct; 101(5):422-431. PubMed ID: 37011414
[TBL] [Abstract][Full Text] [Related]
15. TAZ Regulates the Cisplatin Resistance of Epithelial Ovarian Cancer Cells via the ANGPTL4/SOX2 Axis.
Li C; Wang Q; Luo Y; Xiang J
Anal Cell Pathol (Amst); 2022; 2022():5632164. PubMed ID: 36247876
[TBL] [Abstract][Full Text] [Related]
16. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
18. Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer.
Zhang X; Hong S; Yang J; Liu J; Wang Y; Peng J; Wang H; Hong L
Anticancer Drugs; 2023 Jan; 34(1):29-43. PubMed ID: 35946506
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA ZEB1-AS1 affects paclitaxel and cisplatin resistance by regulating MMP19 in epithelial ovarian cancer cells.
Dai C; Xu P; Liu S; Xu S; Xu J; Fu Z; Cao J; Lv M; Zhou J; Liu G; Zhang H; Jia X
Arch Gynecol Obstet; 2021 May; 303(5):1271-1281. PubMed ID: 33151424
[TBL] [Abstract][Full Text] [Related]
20. Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis.
Han B; Liu Y; Zhang Q; Liang L
J Proteomics; 2023 Mar; 274():104777. PubMed ID: 36427803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
